PERCEPTIVE ADVISORS LLC
Q3 2026 Form 13-F

NEW YORK, NEW YORK
CIK 0001224962 · CRD 154703 · SEC-registered investment adviser
$5.7B Reported Value Total

PERCEPTIVE ADVISORS reports 26 total accounts under management (AUM). There are 26 discretionary accounts valued at $11,765,315,630, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
29 funds · $11.7B gross asset value
Hedge Fund: $10.5B · Venture Capital Fund: $713.7M · Private Equity Fund: $480.2M · Other: $14.7M
Source: Form ADV filed 2026-07-13
Reported value
$5.7B
Quarter over quarter
—
Holdings
—
Top-10 concentration
—

Key People

Form ADV owners & control persons
Joseph Eric Edelman
CHIEF EXECUTIVE OFFICER AND PORTFOLIO MANAGER
Adam Leo Stone
CHIEF INVESTMENT OFFICER
Shmuel Mordechai Cohn
CHIEF FINANCIAL OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $5.7B
Positions 99
Change in reported value -13.8%
New positions 23
Exited positions 25
Position turnover 38.7%
Top-10 concentration 49.7%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
99 $5.7B
Q2 2026 13F
Filed Aug 14, 2026
101 $6.7B
Q1 2026 13F
Filed May 15, 2026
91 $5.1B
Q4 2025 13F
Filed Feb 17, 2026
111 $5.6B
Q3 2025 13F
Filed Nov 14, 2025
90 $3.5B
Q2 2025 13F
Filed Aug 14, 2025
82 $2.7B
Q1 2025 13F
Filed May 15, 2025
86 $2.8B
Q4 2024 13F
Filed Feb 14, 2025
97 $3.6B
Q3 2024 13F
Filed Nov 14, 2024
102 $4.7B
Q2 2024 13F
Filed Aug 14, 2024
107 $4.2B
Q1 2024 13F
Filed May 15, 2024
105 $5.7B
Q4 2023 13F
Filed Feb 14, 2024
97 $4.5B
Q3 2023 13F
Filed Nov 14, 2023
87 $3.0B
Q2 2023 13F
Filed Aug 14, 2023
88 $3.5B
Q1 2023 13F
Filed May 15, 2023
98 $3.4B
Q4 2022 13F
Filed Feb 14, 2023
94 $3.6B
Q3 2022 13F
Filed Nov 14, 2022
113 $3.4B
Q2 2022 13F
Filed Aug 15, 2022
107 $3.2B
Q1 2022 13F
Filed May 16, 2022
131 $5.0B
Q4 2021 13F
Filed Feb 14, 2022
140 $6.5B

34 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 PRAX PRAXIS PRECISION MEDICINES I $589.7M 10.27%
2 AMLX AMYLYX PHARMACEUTICALS INC $307.7M 5.36%
3 SYRE SPYRE THERAPEUTICS INC $292.1M 5.09%
4 MRNA P MODERNA INC $269.6M 4.7%
5 CELC CELCUITY INC $252.9M 4.4%
6 RYTM RHYTHM PHARMACEUTICALS INC $241.1M 4.2%
7 ROIV ROIVANT SCIENCES LTD $238.1M 4.15%
8 RLAY RELAY THERAPEUTICS INC $229.8M 4.0%
9 ASND ASCENDIS PHARMA A/S $221.3M 3.86%
10 TVTX TRAVERE THERAPEUTICS INC $208.6M 3.63%
11 FRNM FREENOME INC $198.5M 3.46%
12 EWTX EDGEWISE THERAPEUTICS INC $168.0M 2.93%
13 INBX INHIBRX BIOSCIENCES INC $129.3M 2.25%
14 NRIX NURIX THERAPEUTICS INC $127.4M 2.22%
15 KARD KARDIGAN INC $121.0M 2.11%
16 MGTX MEIRAGTX HLDGS PLC $118.7M 2.07%
17 PTGX PROTAGONIST THERAPEUTICS INC $117.9M 2.05%
18 IMTX IMMATICS N.V $98.7M 1.72%
19 ZYME ZYMEWORKS INC $93.9M 1.64%
20 ORKA ORUKA THERAPEUTICS INC $89.3M 1.56%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings